Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial imaging recommendations for Vasovist angiography.

Mike Hartmann1, Andrea J Wiethoff, Hans-Rainer Hentrich

  • 1EPIX Pharmaceuticals, 161 First Street Cambridge, MA 02142, USA. mhartmann@epixpharma.com

European Radiology
|June 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening: The VICTORION-PLAQUE primary prevention trial.

American heart journal·2025
Same author

Impact of concentration and dilution of three macrocyclic gadolinium-based contrast agents on MRI signal intensity at 1.5T and 3T and different pulse sequences: results of a phantom study in human plasma.

Acta radiologica (Stockholm, Sweden : 1987)·2020
Same author

Comparison of the Relaxivities of Macrocyclic Gadolinium-Based Contrast Agents in Human Plasma at 1.5, 3, and 7 T, and Blood at 3 T.

Investigative radiology·2019
Same author

Contrast-enhanced magnetic resonance imaging for the detection of ruptured coronary plaques in patients with acute myocardial infarction.

PloS one·2017
Same author

Quantitative diffusion-weighted imaging and dynamic contrast-enhanced characterization of the index lesion with multiparametric MRI in prostate cancer patients.

Journal of magnetic resonance imaging : JMRI·2016
Same author

Quantitative R2* MRI of the liver with rician noise models for evaluation of hepatic iron overload: Simulation, phantom, and early clinical experience.

Journal of magnetic resonance imaging : JMRI·2015

Vasovist, a novel blood pool contrast agent, enhances Magnetic Resonance Angiography (MRA) imaging. Its protein-binding properties allow for lower doses and improved vascular visualization.

Area of Science:

  • Radiology
  • Medical Imaging
  • Pharmacology

Background:

  • Magnetic Resonance Angiography (MRA) requires effective contrast agents for vascular imaging.
  • Existing extracellular fluid contrast agents have limitations in vascular retention and required dosage.
  • Development of targeted blood pool agents can improve MRA efficacy.

Purpose of the Study:

  • To introduce Vasovist, a new Gadolinium-based blood pool contrast agent for MRA.
  • To evaluate the efficacy and technical aspects of using Vasovist in MRA.
  • To provide preliminary recommendations for optimizing MRA protocols with Vasovist.

Main Methods:

  • Vasovist is a low molecular weight Gadolinium chelate designed to bind plasma proteins.
  • Administration involves standard extracellular contrast injection protocols with potential adjustments for extended phase imaging.

Related Experiment Videos

  • Optimization of imaging parameters like repetition time (TR) and flip angle for steady-state imaging was explored.

    • Main Results:

    • Vasovist demonstrates strong binding to plasma proteins, increasing relaxivity and vascular retention time.
    • Higher efficiency allows for smaller doses and lower injection volumes compared to traditional agents.
    • Dynamic and steady-state MRA are achievable with Vasovist using routine MRA parameters and adjusted protocols.

    Conclusions:

    • Vasovist is an effective blood pool contrast agent for MRA.
    • Its properties enable reduced dosage and improved intravascular signal.
    • Clinical trial experience provides a basis for technical recommendations for Vasovist-enhanced MRA.